Forty Seven Inc., of Menlo Park, Calif., said it inked a deal with Darmstadt, Germany-based Merck KGaA to conduct a phase Ib trial combining CD47-targeting candidate Hu5F9-G4 with PD-1/PD-L1-targeting Bavencio (avelumab) in patients with ovarian cancer.